Literature DB >> 22258987

Antibiotic therapy for preventing infections in patients with acute stroke.

Willeke F Westendorp1, Jan-Dirk Vermeij, Frederique Vermeij, Heleen M Den Hertog, Diederik W J Dippel, Diederik van de Beek, Paul J Nederkoorn.   

Abstract

BACKGROUND: Stroke is the main cause of disability in high income countries and ranks second as a cause of death worldwide. Infections occur frequently after stroke and may adversely affect outcome. Preventive antibiotic therapy in the acute phase of stroke may reduce infections and improve outcome.
OBJECTIVES: 1. To assess whether preventive antibiotic therapy in patients with acute stroke reduces the risk of dependency and death at follow-up. 2. To assess whether preventive antibiotic therapy in patients with acute stroke reduces infection rate. SEARCH
METHODS: We searched the Cochrane Stroke Group's Trials Register (October 2010); The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 3); MEDLINE (1950 to October 2010) and EMBASE (1980 to October 2010). In an effort to identify further published, unpublished and ongoing trials we searched trials and research registers, scanned reference lists and contacted authors, colleagues and researchers in the field. SELECTION CRITERIA: Randomised controlled trials (RCTs) of preventive antibiotic therapy versus control (placebo or open control) in patients with acute ischaemic or haemorrhagic stroke. DATA COLLECTION AND ANALYSIS: Two authors independently selected articles and performed data extraction; we discussed and resolved discrepancies in a consensus meeting with a third observer. We contacted the study authors to obtain missing data when required. An independent observer assessed methodological quality. We calculated relative risks (RRs) for dichotomous outcomes, assessed heterogeneity amongst included studies and performed subgroup analyses on study quality. MAIN
RESULTS: We included five studies involving 506 patients. Study population, study design, type of antibiotic and definition of infection differed considerably. The number of patients who died in the preventive antibiotic group was non-significantly reduced (33/248 (13%) versus 38/258 (15%), RR 0.85, 95% confidence interval (CI) 0.47 to 1.51); the number of dependent patients in the preventive antibiotic therapy group was also non-significantly reduced (97/208 (47%) versus 127/208 (61%), RR 0.67, 95% CI 0.32 to 1.43). Preventive antibiotic therapy did reduce the incidence of infections in patients with acute stroke from 36% to 22% (36/166 (22%) versus 61/169 (36%), RR 0.58, 95% CI 0.43 to 0.79). No major side-effects of preventive antibiotic therapy were reported. AUTHORS'
CONCLUSIONS: In this meta-analysis, preventive antibiotic therapy seemed to reduce the risk of infection, but did not reduce the number of dependent or deceased patients. However, the included studies were small and heterogeneous. Large randomised trials are urgently needed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22258987     DOI: 10.1002/14651858.CD008530.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  34 in total

Review 1.  The immunology of acute stroke.

Authors:  Ángel Chamorro; Andreas Meisel; Anna M Planas; Xabier Urra; Diederik van de Beek; Roland Veltkamp
Journal:  Nat Rev Neurol       Date:  2012-06-05       Impact factor: 42.937

2.  Infections Increase the Risk of 30-Day Readmissions Among Stroke Survivors.

Authors:  Amelia K Boehme; Erin R Kulick; Michelle Canning; Trevor Alvord; Bijan Khaksari; Setareh Omran; Joshua Z Willey; Mitchell S V Elkind
Journal:  Stroke       Date:  2018-12       Impact factor: 7.914

Review 3.  Prophylactic Antibiotic Therapy for Preventing Poststroke Infection.

Authors:  Stefan Schwarz
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

4.  Stroke: long-term effect of infections after stroke.

Authors:  Diederik van de Beek
Journal:  Nat Rev Neurol       Date:  2013-02-19       Impact factor: 42.937

5.  Infections present on admission compared with hospital-acquired infections in acute ischemic stroke patients.

Authors:  Amelia K Boehme; Andre D Kumar; Adrianne M Dorsey; James E Siegler; Monica S Aswani; Michael J Lyerly; Dominique J Monlezun; Alexander J George; Karen C Albright; Timothy M Beasley; Sheryl Martin-Schild
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-08-15       Impact factor: 2.136

6.  Very Low Frequency Heart Rate Variability Predicts the Development of Post-Stroke Infections.

Authors:  Dirk Brämer; Albrecht Günther; Sven Rupprecht; Samuel Nowack; Josephine Adam; Fenja Meyer; Matthias Schwab; Ralf Surber; Otto W Witte; Heike Hoyer; Dirk Hoyer
Journal:  Transl Stroke Res       Date:  2019-01-07       Impact factor: 6.829

7.  Post-stroke infections exacerbate ischemic brain injury in middle-aged rats: immunomodulation and neuroprotection by progesterone.

Authors:  S Yousuf; F Atif; I Sayeed; J Wang; D G Stein
Journal:  Neuroscience       Date:  2012-10-16       Impact factor: 3.590

8.  Preventive Ceftriaxone in Patients with Stroke Treated with Intravenous Thrombolysis: Post Hoc Analysis of the Preventive Antibiotics in Stroke Study.

Authors:  Jan-Dirk Vermeij; Willeke F Westendorp; Yvo B Roos; Matthijs C Brouwer; Diederik van de Beek; Paul J Nederkoorn
Journal:  Cerebrovasc Dis       Date:  2016-06-24       Impact factor: 2.762

9.  Preventive Antibiotics and Delayed Cerebral Ischaemia in Patients with Aneurysmal Subarachnoid Haemorrhage Admitted to the Intensive Care Unit.

Authors:  Celine S Gathier; Evelien A Oostdijk; Gabriel J E Rinkel; Sanne M Dorhout Mees; Mervyn D I Vergouwen; Anne Marie G A de Smet; Diederik van de Beek; W Peter Vandertop; Dagmar Verbaan; Ale Algra; Marc J M Bonten; Walter M van den Bergh
Journal:  Neurocrit Care       Date:  2016-02       Impact factor: 3.210

10.  Inpatient rehabilitation centers and concern for increasing volume of ischemic stroke patients requiring rehabilitation.

Authors:  James E Siegler; Amelia K Boehme; Bethena D Fowler; Alexander J George; Dominique J Monlezun; Karen C Albright; T Mark Beasley; Sheryl Martin-Schild
Journal:  South Med J       Date:  2013-12       Impact factor: 0.954

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.